TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06385080: A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 287 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$9,542,610

Rescue Site Savings

+$6,283,200

Unlock Full NCT06385080 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06385080 Rescue Dossier →